CN112368049B - 作为gpr142激动剂的三唑苯甲酰胺衍生物 - Google Patents

作为gpr142激动剂的三唑苯甲酰胺衍生物 Download PDF

Info

Publication number
CN112368049B
CN112368049B CN201980044866.3A CN201980044866A CN112368049B CN 112368049 B CN112368049 B CN 112368049B CN 201980044866 A CN201980044866 A CN 201980044866A CN 112368049 B CN112368049 B CN 112368049B
Authority
CN
China
Prior art keywords
alkyl
compound
formula
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980044866.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112368049A (zh
Inventor
A·赫克尔
R·奥古斯丁
S·班德霍兹
S·弗拉蒂尼
B·韦伦佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN112368049A publication Critical patent/CN112368049A/zh
Application granted granted Critical
Publication of CN112368049B publication Critical patent/CN112368049B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980044866.3A 2018-07-04 2019-06-28 作为gpr142激动剂的三唑苯甲酰胺衍生物 Active CN112368049B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18181580 2018-07-04
EP18181580.4 2018-07-04
PCT/EP2019/067344 WO2020007729A1 (en) 2018-07-04 2019-06-28 Triazole benzamide derivatives as gpr142 agonists

Publications (2)

Publication Number Publication Date
CN112368049A CN112368049A (zh) 2021-02-12
CN112368049B true CN112368049B (zh) 2024-03-29

Family

ID=62873186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044866.3A Active CN112368049B (zh) 2018-07-04 2019-06-28 作为gpr142激动剂的三唑苯甲酰胺衍生物

Country Status (5)

Country Link
US (1) US11179371B2 (https=)
EP (1) EP3817811B1 (https=)
JP (1) JP7391055B2 (https=)
CN (1) CN112368049B (https=)
WO (1) WO2020007729A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179371B2 (en) 2018-07-04 2021-11-23 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as GPR142 agonists
WO2022188792A1 (zh) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150134731A (ko) * 2014-05-22 2015-12-02 이화여자대학교 산학협력단 오로라 키나아제 억제 활성을 갖는 신규한 트리아졸일살리실아마이드 유도체
WO2018014800A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Cyclohexyl benzamide compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005014621D1 (de) * 2004-03-09 2009-07-09 Boehringer Ingelheim Pharma 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
WO2010093849A2 (en) 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
US11179371B2 (en) 2018-07-04 2021-11-23 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as GPR142 agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150134731A (ko) * 2014-05-22 2015-12-02 이화여자대학교 산학협력단 오로라 키나아제 억제 활성을 갖는 신규한 트리아졸일살리실아마이드 유도체
WO2018014800A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Cyclohexyl benzamide compounds

Also Published As

Publication number Publication date
CN112368049A (zh) 2021-02-12
US11179371B2 (en) 2021-11-23
US20210267947A1 (en) 2021-09-02
JP7391055B2 (ja) 2023-12-04
WO2020007729A1 (en) 2020-01-09
JP2021529189A (ja) 2021-10-28
EP3817811B1 (en) 2024-04-03
EP3817811A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
US12358875B2 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
KR102692309B1 (ko) Fxr (nr1h4) 조정 화합물
TWI395741B (zh) 嗒酮衍生物
TW202115040A (zh) 類升糖素肽1受體促效劑
JP6130399B2 (ja) 新規アゼチジン誘導体、医薬組成物およびそれらの使用
KR20130109943A (ko) 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체
JP5821079B2 (ja) ビシクロ置換ピラゾロン−アゾ誘導体の塩、その製造方法及びその使用
WO2011042798A1 (en) Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
JP2013530963A (ja) 新規のｇｌｐ−１受容体安定化薬および調節薬
KR20240000510A (ko) 소르틸린 활성 조절제
KR20240007137A (ko) 소르틸린 활성 조절제
CN120344520A (zh) 胰高血糖素样肽1受体激动剂
CA2696237C (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
TWI861165B (zh) 新穎嗒
CN112368049B (zh) 作为gpr142激动剂的三唑苯甲酰胺衍生物
US20240132514A1 (en) Pyridine derivatives as modulators of sortilin activity
KR20240155871A (ko) 소르틸린 의존성 질병의 치료를 위한 아미노산 기반 카바메이트 및/또는 요소
US10519105B2 (en) KCNQ2-5 channel activator
KR102647513B1 (ko) Fxr 활성효과를 가지는 시나믹아마이드 유도체, 이를 유효성분으로 함유하는 약학적 조성물 및 이의 제조방법
CN103547563B (zh) 可用作胰高血糖素受体拮抗剂的联苯基衍生物
JP7502564B2 (ja) ２－［（チオフェン－２－イル）ホルムアミド］－ｎ－（フェニル）－２－メチルプロパンアミド誘導体及びその医薬としての使用
WO2022131146A1 (ja) 含窒素複素環式化合物
TW202442226A (zh) 化合物
CN116135851A (zh) 一种芳香胺化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant